Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial

Autor: André, Fabrice, Hee Park, Yeon, Kim, Sung-Bae, Takano, Toshimi, Im, Seock-Ah, Borges, Giuliano, Lima, Joao Paulo, Aksoy, Sercan, Gavila Gregori, Joaquin, De Laurentiis, Michelino, Bianchini, Giampaolo, Roylance, Rebecca, Miyoshi, Yasuo, Armstrong, Anne, Sinha, Rajni, Ruiz Borrego, Manuel, Lim, Elgene, Ettl, Johannes, Yerushalmi, Rinat, Zagouri, Flora, Duhoux, Francois P, Fehm, Tanja, Gambhire, Dhiraj, Cathcart, Jillian, Wu, Cai, Chu, Changan, Egorov, Anton, Krop, Ian *
Zdroj: In The Lancet 27 May-2 June 2023 401(10390):1773-1785
Databáze: ScienceDirect